Cipla Q1 FY27 result: Net profit jumps 42% QoQ; India business records 12% annual growth

However, on a year-on-year (YoY) basis, the net profit has fallen 39% from ₹1,298 crore seen in Q1 FY26.

The pharm major reported total revenue from operations of ₹7,119 crore for the quarter under review, compared with ₹6,541 crore in the previous quarter and ₹6,957 crore in the year-ago period, reflecting an increase of 9% quarter-on-quarter (QoQ) and 2% YoY.

On the operational level, Cipla’s earnings before interest, taxes, depreciation and amortisation (EBITDA) stood at ₹1,192 crore, marking a decline of 34% from ₹1,778 crore in Q1 FY26. Sequentially, the EBITDA has improved 25% from ₹955 crore.

The company’s EBITDA margin expanded to 16.74% in contrast to 14.6% QoQ, while on a yearly basis it has contracted from 25.56%.

For Q1 FY27, Cipla maintained a strong net cash position of ₹9,494 crore and said that its debt largely comprises lease liabilities and working capital requirements.

The company reported R&D investments of ₹486 crore during the quarter, accounting for 6.8% of sales, marking a 12.3% year-on-year increase. This was driven by higher product filings and ongoing development initiatives.

“Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front,” said Achin Gupta MD and Global CEO, Cipla.

Market update

Cipla Limited said the One India business recorded its highest-ever quarterly sales, registering a growth of 12% YoY, while the chronic portfolio mix improved to 60.4% during the period.

“Our One-India business grew at solid 12% YoY. Branded Prescription business delivered a robust growth, with key therapies outpacing the market, Trade Generics recorded healthy growth and Anchor brands of consumer health business maintained leadership position,” said Gupta.

In North America, the company registered a revenue of $162 million for the quarter under review. For the One Africa business, Cipla stated that the South Africa private market recorded secondary growth of 6.5%.

Gupta also said that the company expects continued sequential growth in North America, supported by an upcoming product pipeline.

In the Emerging Markets and Europe segment, the drugmaker’s focused market strategy supported a 5% yearly growth in USD terms, with an uptick in both DTM and B2B segments, along with sustained overall margins.

Cipla share price trends

Following the earnings, Cipla shares were trading lower. At 12:40 PM, Cipla shares were trading at ₹1,386 apiece on the National Stock Exchange, declining 2.06%.

The stock has touched an intraday low of ₹1,373.60 per share, after opening at ₹1,415.10 on Thursday. Its day’s high was at ₹1,426.90 per share.

From the beginning of the year, Cipla shares have slipped 8%. Over a month’s time, the stock has fallen 4%, while it climbed 5% in the past six months.

Shares of the firm had hit a 52-week high of ₹1,673 on October 23, 2025, and a 52-week low of ₹1,165.70 on April 2, 2026.

According to NSE data, as of July 23, 2026, Cipla has a total market capitalisation of ₹1.11 lakh crore.